Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Todd C. Zion
Observed names:
Todd C Zion,
Todd Zion
Institution:
Akston Biosciences (United States)
Observed institution:
Akston Biosciences (United States)
ORCID:
0000-0002-9757-0020
Observed ORCID:
0000-0002-9757-0020
OpenAlex ID:
A5070545787
Works
12
Awards
3
Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452
2021
·
David G. Alleva
, Andrea R. Delpero
, et al.
·
Vaccine
·
39
Ultra-long-acting recombinant insulin for the treatment of diabetes mellitus in dogs
2022
·
Sean E. Hulsebosch
, Jully Pires
, et al.
·
Journal of Veterinary Internal Medicine
·
28
A randomized phase I/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452
2023
·
Eline A. Feitsma
, Yester F. Janssen
, et al.
·
Vaccine
·
16
Phase I interim results of a phase I/II study of the IgG-Fc fusion COVID-19 subunit vaccine, AKS-452
2022
·
Yester F. Janssen
, Eline A. Feitsma
, et al.
·
Vaccine
·
16
PDF
An ultra-long-acting recombinant insulin for the treatment of diabetes mellitus in cats
2021
·
Chen Gilor
, Sean E. Hulsebosch
, et al.
·
Journal of Veterinary Internal Medicine
·
14
PDF
An antigen-specific immunotherapeutic, AKS-107, deletes insulin-specific B cells and prevents murine autoimmune diabetes
2024
·
David G. Alleva
, Andrea R. Delpero
, et al.
·
Frontiers in Immunology
·
11
PDF
Glucose-Sensitive Nanoparticles for Controlled Insulin Delivery
2003
·
Todd C. Zion
, Henry H. Tsang
, et al.
·
DSpace@MIT (Massachusetts Institute of Technology)
·
11
Glucose-responsive materials for self-regulated insulin delivery
2004
·
Todd C. Zion
·
DSpace@MIT (Massachusetts Institute of Technology)
·
6
Immunogenicity phase II study evaluating booster capacity of nonadjuvanted AKS-452 SARS-Cov-2 RBD Fc vaccine
2024
·
David G. Alleva
, Eline A. Feitsma
, et al.
·
npj Vaccines
·
2
PDF
Abstract P1-21-05: A novel long-acting insulin for cancer therapy reduces xenograft tumor growth
2020
·
Lynsey M Fettig
, Xihong Zhang
, et al.
·
Cancer Research
·
1
The antigen-specific immunotherapy, AKS-107, selectively depletes anti-insulin B lymphocytes in the pancreas and reduces insulitis in T1D-prone mice 2259549
2026
·
Tyler Jenkins
, Jack McAninch
, et al.
·
The Journal of Immunology
PDF
Abstract P4-02-01: Targeting insulin receptor in estrogen receptor positive breast cancer
2022
·
Jingran Cao
, Lynsey M. Fettig
, et al.
·
Cancer Research
Show more works
View as search
Works count:
12
Citation count:
144
H-index:
7
I10-index:
7
Year
Topic
Type
